In-Vitro Fertilization Market Size, Share & Trends Analysis Report By Instrument (Disposable Devices, Culture Media, Capital Equipment), By Procedure Type, By End Use, By Region, And Segment Forecasts, 2020 - 2027

In-Vitro Fertilization Market Size, Share & Trends Analysis Report By Instrument (Disposable Devices, Culture Media, Capital Equipment), By Procedure Type, By End Use, By Region, And Segment Forecasts, 2020 - 2027

The global in-vitro fertilization market size is expected to reach USD 37.7 billion by 2027, expanding at a CAGR of 9.5%, based on a new report by Grand View Research, Inc. The market is driven by increasing incidence of infertility owing to lifestyle changes, government initiatives to provide better reimbursement policies, and the continuous efforts by the industry contributors. Expansion of fertility procedures for treating male infertility, such as ICSI, is projected to positively influence the growth in near future.

Moreover, the availability of genomic testing enabling the prevention of the transfer of genetic disease during in-vitro fertilization (IVF) use is further expected to drive the IVF market. The increase in the number of IVF treatment has led more insurance players to cover the procedures. This has ultimately led to competitive pricing and has moderated the IVF treatment costs as the procedure has been a successfully practiced technology, which has driven the market with more treatment standardization and automation.

The behavioral shift in the society is the major factor contributing to the decreased Total Fertility Rate (TFR). These factors include an increasing number of women in the labor force, the increased age of the first birth, a shift from rural to urban societies, lower marriage rates, and postponement of marriage.

Obesity is another factor leading to an increase in infertility. The fat deposited on women’s abdomen prevents follicular stimulation and produces male hormones. In case of males, rising fat deposits decrease testosterone levels and can result in lowered sperm production. Doctors recommend weight loss in men prior to fertility treatments along with proper maintenance of Body Mass Index (BMI). The U.S. Endocrine Society has established the use of Letrozole to increase the testosterone levels in obese patients.

Further key findings from the study suggest:

  • Culture media dominated the overall in-vitro fertilization market in terms of revenue in 2019. With the increasing government funding and industrial support for employees for egg/sperm freezing, the demand for cryopreservation and the required media for it, is expected to witness growth
  • Moreover, the increasing number of egg/sperm donor banks is expected to drive the demand for sperm, egg, and embryo processing media during the forecast period
  • The fresh non-donor segment dominated the IVF market in 2019. According to the 2003 - 2012 trends by the CDC, the number of fresh non-donors banking the eggs/embryos for future use has drastically increased in U.S.
  • Europe dominated the procedure and instrument market for in-vitro fertilization in 2019. High quality of treatment offered at the most economical price, and the adherence to medical standards have contributed to its market leadership
  • In Europe, the NHS covers three IVF cycles and has also started providing coverage for gametes freezing. Moreover, the region is an attraction for international clients as countries, such as Spain, have the highest number of egg donors. The clinics also provide sex identification and other IVF treatments, which are not offered in North America
  • North America also accounted for a significant share of the market in 2019. The standardization of procedures through automation, regulatory reforms, government funding for egg/sperm storage, and industry players introducing more IVF treatments are some contributing factors for market growth in the region
  • The presence of favorable reimbursement framework (implementation of USD 50 million 5-year plans by the U.S Department of Defense for sperm/egg freezing coverage) is also expected to drive regional market growth over the next six years. The increasing number of clinics undertaking newer techniques to offer better fertility success rates is also expected to increase the demand in the region
  • The demand for IVF treatment is expected to boom in APAC owing to fertility tourism and increasing penetration and awareness of the treatment in the developing economies of the region
  • The Asia Pacific Initiative on Reproduction (ASPIRE), the task force of clinicians and scientists is involved in the monitoring and management of fertility and Assisted Reproductive Technology (ART). Such initiatives promote awareness levels thereby, driving the market
  • Industry contributors are introducing newer automation to shift the IVF treatment from invasive to a minimally invasive or non-invasive procedure. The industry players are also working on technologies, which can enable older women to have enhanced fertility rates
  • Some of the key players in the market include EMD Serono Inc.; Boston IVF; OvaScience; Thermo Fisher Scientific Inc.; Vitrolife AB; Irvine Scientific; CooperSurgical, Inc.; Cook Medical Inc.; Genea Biomedx and Progyny Inc.
  • In October 2018, Vitrolife entered into a licensing and commercialization agreement with Illumina, Inc. This will provide Vitrolife with exclusive distribution, development, and commercialization rights to Illumina’s preimplantation genetic testing business in Europe, Middle East and Africa, and North America.
Please note The report will be updated with the latest data and delivered to you within 2-3 business days.


Table of Contents Chapter 1 Research Objectives 1.1 Objective - 1: 1.2 Objective - 2: Chapter 2 Executive Summary 2.1 Market Outlook 2.2 Segment Outlook 2.3 Competitive Insights Chapter 3 Market Variables, Trends & Scope 3.1 Market Lineage Outlook 3.1.1 Parent Market Outlook 3.1.2 Related/Ancillary Market Outlook 3.2 Market Segmentation 3.3 Penetration & Growth Prospect Mapping 3.4 Clinical Trials 3.5 User Perspective Analysis 3.5.1 Consumer Behavior Analysis 3.5.2 Market Influencer Analysis 3.6 Regulatory Framework & Reimbursement Scenario 3.6.1 North America 3.6.2 Europe 3.6.3 Asia Pacific 3.6.4 Latin America 3.6.5 Middle East & Africa 3.7 Market Dynamics 3.7.1 Market Driver Analysis 3.7.1.1 Rising reprotourism 3.7.1.2 Technological advancements in IVF 3.7.1.3 Favorable government funding 3.7.1.4 Late initiation of family 3.7.1.5 Increasing incidence rate of male and female infertility 3.7.1.6 Mergers and acquisitions (M&A) 3.7.2 Market Restraint Analysis 3.7.2.1 High cost of IVF treatment 3.7.2.2 Lack of regulatory framework and uniform regulations 3.7.3 Porter’s Five Forces Analysis 3.7.3.1 Bargaining power of buyers 3.7.3.2 Bargaining power of suppliers 3.7.3.3 Competitive rivalry 3.7.3.4 Threat of new entrants 3.7.3.5 Threat of substitutes 3.8 Business Environment Analysis Tools 3.8.1 Swot Analysis, By Pestel 3.8.1.1 Political & legal 3.8.1.2 Economic 3.8.1.3 Technological 3.8.2 Major Deals & Strategic Alliances Analysis 3.8.2.1 Joint ventures 3.8.2.2 Mergers & acquisitions Chapter 4 In-Vitro Fertilization (IVF) Market: Instrument Analysis 4.1 In-Vitro Fertilization (IVF) Market Share Analysis, 2019 & 2027 4.2 Segment Dashboard 4.3 In-Vitro Fertilization (IVF) Market, by Instrument, 2016 to 2027 4.4 Market Size & Forecasts and Trend Analysis, 2016 to 2027 for the Instrument 4.4.1 Culture Media 4.4.1.1 Culture media market, 2016 - 2027 (USD Million) 4.4.2 Disposable Devices 4.4.2.1 Disposable devices market, 2016 - 2027 (USD Million) 4.4.3 Capital Equipment 4.4.3.1 Capital equipment market, 2016 - 2027 (USD Million) Chapter 5 In-Vitro Fertilization (IVF) Market: Procedure Type Analysis 5.1 In-Vitro Fertilization (IVF) by Type Market Share Analysis, 2019 & 2027 5.2 Segment Dashboard 5.3 Global IVF Market, by Treatment Type, 2016 - 2027 5.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the Treatment Type 5.4.1 Fresh Nondonor 5.4.1.1 Fresh nondonor market, 2016 - 2027 (USD Million) 5.4.2 Frozen Nondonor 5.4.2.1 Frozen nondonor market, 2016 - 2027 (USD Million) 5.4.3 Fresh Donor 5.4.3.1 Fresh donor market, 2016 - 2027 (USD Million) 5.4.4 Frozen Donor 5.4.4.1 Frozen donor market, 2016 - 2027 (USD Million) Chapter 6 In-Vitro Fertilization (IVF) Market: End-use Analysis 6.1 In-Vitro Fertilization (IVF) End-use Market Share Analysis, 2019 & 2027 6.2 Segment Dashboard 6.3 In-Vitro Fertilization (IVF) Market, by End Use, 2016 - 2027 6.4 Market Size & Forecasts and Trend Analysis, 2016 to 2027 for the Following End Use 6.4.1 Fertility Clinics 6.4.1.1 Fertility clinics market, 2016 - 2027 (USD Million) 6.4.2 Hospitals & Other Settings 6.4.2.1 Hospitals & other settings market, 2016 - 2027 (USD Million) Chapter 7 Regional Outlook 7.1 Definitions & Scope 7.2 Regional Market Share Analysis, 2019 & 2027 7.3 Regional Market Dashboard 7.4 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends) 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological) 7.5.1 North America 7.5.2 Europe 7.5.3 Asia Pacific 7.5.4 Latin America 7.5.5 MEA 7.6 Market Size, & Forecasts and Trend Analysis, 2019 to 2027 7.6.1 North America 7.6.1.1 North America in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.1.2 U.S. 7.6.1.2.1 U.S. in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.1.3 Canada 7.6.1.3.1 Canada in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.2 Europe 7.6.2.1 Europe in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.2.2 U.K. 7.6.2.2.1 U.K. in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.2.3 Germany 7.6.2.3.1 Germany in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.2.4 France 7.6.2.4.1 France in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.2.5 Italy 7.6.2.5.1 Italy in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.2.6 Spain 7.6.2.6.1 Spain in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.2.7 Netherlands 7.6.2.7.1 Netherlands in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.2.8 Switzerland 7.6.2.8.1 Switzerland in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.2.9 Belgium 7.6.2.9.1 Belgium in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.3 Asia Pacific 7.6.3.1 Asia Pacific in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.3.2 Japan 7.6.3.2.1 Japan in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.3.3 China 7.6.3.3.1 China in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.3.4 India 7.6.3.4.1 India in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.4 Latin America 7.6.4.1 Latin America in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.4.2 Brazil 7.6.4.2.1 Brazil in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.4.3 Mexico 7.6.4.3.1 Mexico in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.5 Middle East And Africa 7.6.5.1 MEA in-vitro fertilization market, 2016 - 2027 (USD Million) 7.6.5.2 South Africa 7.6.5.2.1 South Africa in-vitro fertilization market, 2016 - 2027 (USD Million) Chapter 8 Competitive Analysis 8.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players 8.2 Vendor Landscape 8.2.1 Strategy Mapping 8.2.2 Launch Of New Products: 8.2.3 Merger And Acquisition: 8.2.4 Geographical Expansion: 8.2.5 Partnerships: 8.3 Public Companies 8.3.1 Company Market Position Analysis (Revenue, Geographic Presence, Product Portfolio, Key Serviceable Industries, Key Alliances) 8.4 Private Companies 8.4.1 List Of Key Emerging Companies/Technology 8.4.2 Company Market Position Analysis (Geographic Presence, Product Portfolio, Key Alliance, Industry Experience) 8.5 Company Profiles 8.5.1 OVASCIENCE, INC. 8.5.1.1 Company overview 8.5.1.2 Financial performance 8.5.1.3 Product benchmarking 8.5.1.4 Strategic initiatives 8.5.1.5 SWOT analysis 8.5.2 VITROLIFE 8.5.2.1 Company overview 8.5.2.2 Financial performance 8.5.2.3 Product benchmarking 8.5.2.4 Strategic initiatives 8.5.2.5 SWOT analysis 8.5.3 EMD SERONO, INC. 8.5.3.1 Company overview 8.5.3.2 Financial performance 8.5.3.3 Product benchmarking 8.5.3.4 Strategic initiatives 8.5.3.5 SWOT analysis 8.5.4 IRVINE SCIENTIFIC 8.5.4.1 Company overview 8.5.4.2 Financial performance 8.5.4.3 Product benchmarking 8.5.4.4 Strategic initiatives 8.5.4.5 SWOT analysis 8.5.5 THE COOPER COMPANIES, INC. 8.5.5.1 Company overview 8.5.5.2 Product benchmarking 8.5.5.3 SWOT analysis 8.5.6 COOK MEDICAL (COOK GROUP) 8.5.6.1 Company overview 8.5.6.2 Product benchmarking 8.5.6.3 Strategic initiatives 8.5.6.4 SWOT analysis 8.5.7 THERMO FISHER SCIENTIFIC, INC. 8.5.7.1 Company overview 8.5.7.2 Financial performance 8.5.7.3 Product benchmarking 8.5.7.4 Strategic initiatives 8.5.7.5 SWOT analysis 8.5.8 GENEA BIOMEDX 8.5.8.1 Company overview 8.5.8.2 Product benchmarking 8.5.8.3 Strategic initiatives 8.5.8.4 SWOT analysis 8.5.9 PROGYNY, INC. 8.5.9.1 Company overview 8.5.9.2 Financial performance 8.5.9.3 Product benchmarking 8.5.9.4 Strategic initiatives 8.5.9.5 SWOT analysis 8.5.10 BOSTON IVF 8.5.10.1 Company overview 8.5.10.2 Financial performance 8.5.10.3 Product benchmarking 8.5.10.4 Strategic initiatives 8.5.10.5 SWOT analysis 8.5.11 ORIGIO 8.5.11.1 Company overview 8.5.11.2 Financial performance 8.5.11.3 Product benchmarking 8.5.11.4 Strategic initiatives 8.5.11.5 SWOT analysis 8.5.12 FERRING PHARMACEUTICAL 8.5.12.1 Company overview 8.5.12.2 Financial performance 8.5.12.3 Product benchmarking 8.5.12.4 Strategic initiatives 8.5.12.5 SWOT analysis 8.5.13 BAYER AG 8.5.13.1 Company overview 8.5.13.2 Financial performance 8.5.13.3 Product benchmarking 8.5.13.4 Strategic initiatives 8.5.13.5 SWOT analysis 8.5.14 MERCK & CO., INC. 8.5.14.1 Company overview 8.5.14.2 Financial performance 8.5.14.3 Product benchmarking 8.5.14.4 Strategic initiatives 8.5.14.5 SWOT analysis 8.5.15 ORGANON 8.5.15.1 Company overview 8.5.15.2 Financial performance 8.5.15.3 Product benchmarking 8.5.15.4 Strategic initiatives 8.5.15.5 SWOT analysis Chapter 9 KOL Commentary & Recommendations Chapter 10 Research Methodology & Scope 10.1 Research Methodology 10.1.1 Information procurement 10.1.1.1 Purchased database: 10.1.1.2 GVR’s internal database 10.1.2 Primary research: 10.2 Research Scope and Assumptions 10.3 List to Data Sources Chapter 11 Report FAQs 11.1 How Do I Trust Your Report Quality/Data Accuracy? 11.2 My Research Requirement Is Very Specific; Can I Customize This Report? 11.3 I have a pre-defined budget. Can I buy chapters/sections of this report? 11.4 How Do You Arrive At These Market Numbers? 11.5 Who Are Your Clients? 11.6 How Will I Receive This Report? Chapter 12 Appendix Chapter 13 Compass - Cloud Based Report Delivery Platform Chapter 14 Related Reports

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook